Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Phase 2 Recruiting
200 enrolled
rbliqbx
Recruiting
800 enrolled
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Phase 2 Recruiting
70 enrolled
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
168 enrolled
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
Phase 1/2 Recruiting
310 enrolled
Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors
Phase 1/2 Recruiting
255 enrolled
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
121 enrolled
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Phase 3 Recruiting
386 enrolled
NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors
Recruiting
4,000 enrolled
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/2 Recruiting
225 enrolled
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
240 enrolled
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
Phase 1 Recruiting
154 enrolled
TLN-372 in Advanced KRAS Mutant Solid Tumors
Phase 1 Recruiting
240 enrolled
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Phase 2 Recruiting
131 enrolled
A Study of BGM-2121 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
35 enrolled
Phase 1a/1b GTB-5550 in Advanced Solid Tumors
Phase 1 Recruiting
175 enrolled
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
Recruiting
6,035 enrolled
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Recruiting
10,000 enrolled
Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Phase 2 Recruiting
35 enrolled
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
Recruiting
800 enrolled
MYTHIC
Phase 1 Recruiting
464 enrolled
A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation
Phase 1 Recruiting
104 enrolled
A Study of HS-20110 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
475 enrolled
PARTHENON
Phase 1/2 Recruiting
180 enrolled
A Study of HDM2024 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
63 enrolled
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Recruiting
1,310 enrolled
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
63 enrolled
TMB-H
Phase 2 Recruiting
30 enrolled
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Phase 2 Recruiting
430 enrolled
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Phase 1 Recruiting
210 enrolled
ICE COMPRESS
Phase 3 Recruiting
777 enrolled
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
Phase 1 Recruiting
54 enrolled
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
Phase 1 Recruiting
128 enrolled
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Phase 1/2 Recruiting
141 enrolled
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Phase 1/2 Recruiting
223 enrolled
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
170 enrolled
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
200 enrolled
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1/2 Recruiting
197 enrolled
CLINCH
Phase 1 Recruiting
156 enrolled
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Phase 1 Recruiting
308 enrolled
A Study of BG-C477 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
310 enrolled
ANTARES
Phase 2 Recruiting
28 enrolled
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
660 enrolled
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Phase 1 Recruiting
63 enrolled
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
Phase 1 Recruiting
105 enrolled
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
180 enrolled
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Phase 1 Recruiting
60 enrolled
ON-TRK
Recruiting
150 enrolled
NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes
Recruiting
100 enrolled
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Phase 1 Recruiting
190 enrolled